DATASHEET: Opto® Cell Line Development Workflow | A4

DATASHEET: Opto® Cell Line Development Workflow

INFO SHEET: TechAccess Subscriptions

TechAccess Subscriptions provide access to Berkeley Lights’ revolutionary workflows no matter
the size of your lab, your customer base, or budget.

eBook: How to Get More Molecules to the Clinic Faster with Automated Cell Line Development

Learn how our Opto CLD workflow can help remove the bottleneck from traditional cell line development.

Webinar: Bring Product Quality Assessment into Early Clone Selection with Opto™ Cell Line Development

CHO cell line selection represents a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. At BPI Europe Digital Week 2021, Renee Tobias discussed how the Opto™ CLD workflow on the Beacon® system can help through accelerating early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process.

Customer Spotlight: Amgen on the Berkeley Lights Platform

Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.

App Note: Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay

Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.

Brochure: Get to Market Faster with the Opto CLD Workflow

Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster. 

Brochure: Increase CDMO Revenue with the Opto CLD Workflow

Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business. 

Webinar: Leveraging Innovative Technologies to Accelerate Biologics Development

At the 2021 BPS EU virtual conference, Beacon user Joaquina Mascarenhas, PhD, at Thermo Fisher Scientific shares how the Berkeley Lights Platform enables their cell line development to move at world class speed and select the best clones.

Webinar: Accelerating Discovery and Development of Antibody Therapeutics

Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.

App Note: FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development

Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.

Webinar: Get More Molecules to The Clinic Faster

Watch our presentation from BPI Digital Week, hosted by Renee Tobias, to hear how our customers are using the Opto™ CLD workflow to find the best cell lines with the most confident monoclonality in just a few day and de-risk their path to IND faster.

Customer Spotlight: Amgen on AbD and CLD

Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.

Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing

Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.

Customer Spotlight: Catalent on CLD

Find out how Catalent Biologics is able to select significantly higher expressing clonal cell lines with the Opto CLD workflow.

Product Tour: The Opto™ CLD Workflow

Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ CLD workflow makes it possible to produce superior cell lines, with >99% monoclonality assurance, in a matter of days.

Poster: Rapid Generation of Production Cell Lines with Superior Titers and >99% Monoclonality for Complex Antibody Molecules

See how the Opto CLD 2.0 Workflow enables rapid generation of cell lines secreting antibodies for both traditional and non-traditional antibodies while acquiring a superior data package.